A Life Sciences VC backed by JV Ventures, IXP,  has announced the launch of its first fund that would be focused towards driving investment in early-stage companies. Furthermore, this fund would be aimed at building a portfolio of B2B companies which will range from pre-seed to Series A stages.

With a greenshoe option of Rs 100 crore, the IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 200 crore. Moreover, the fund plans to create a portfolio of 20-25 companies so as to address gaps in the market for both services and products. Also to note, the fund will invest in innovations within the Life Sciences sector and will cover areas including pharma, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals.

Furthermore, it will co-create companies alongside scientists to develop ideas that address unmet market needs through IXP Venture Studio. It takes a hands-on approach, unlike traditional VCs, and actively participates from concept to scale, wherein, the Venturepreneur Program has been designed to transform scientists into founders.

According to IXP, early-stage companies expect access to larger ecosystems, which include laboratories, networks, and R&D services. Understanding this, IXP meets these demands through PoweRx, the Life Sciences vertical of JV Ventures. Additionally, the VC firm leverages synergies within the group so as to create a winning proposition for portfolio companies.

Going forward, by integrating them into a rich life sciences ecosystem, IXP aims to support scientists and innovators in their entrepreneurial journey.

Furthermore, the VC firm has also noted that it is composed of a robust team, wherein, it understands the capital-intensive nature and long gestation periods pertaining to R&D, thereby steering innovative ideas into the market.